BNP Paribas Bonus Zert PFE 24.06..../ DE000PG1E097 /
11/14/2024 9:20:14 AM | Chg.+0.020 | Bid9:59:10 AM | Ask9:55:39 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
20.030EUR | +0.10% | 20.070 Bid Size: 1,750 |
- Ask Size: - |
Pfizer Inc | - USD | 6/24/2026 | Call |
GlobeNewswire
9/3
Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidat...
GlobeNewswire
8/22
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vacc...
GlobeNewswire
8/16
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and C...
GlobeNewswire
7/17
Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion ...
GlobeNewswire
6/27
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the E...
GlobeNewswire
6/5
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Co...
GlobeNewswire
6/3
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
GlobeNewswire
5/16
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combinatio...
GlobeNewswire
5/9
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medic...
GlobeNewswire
4/30
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire
3/22
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous ...
GlobeNewswire
3/7
BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel B...
GlobeNewswire
3/7
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTe...